Bachem Holding AG stock (CH0012530207): Peptide leader eyes US biotech growth

Bachem Holding AG, a key supplier of peptides for pharmaceuticals, continues to benefit from rising demand in the US biotech sector amid ongoing research into new therapies.

Bachem Holding AG maintains its position as a leading provider of custom peptides and oligonucleotides for the pharmaceutical and biotech industries. The Swiss company specializes in manufacturing high-quality peptide APIs used in drug development, particularly for research into cancer treatments, metabolic disorders, and peptide therapeutics. Recent industry reports highlight sustained demand for Bachem's services from US-based biotech firms, which account for a significant portion of its revenue. The stock traded at approximately 65.50 CHF on the SIX Swiss Exchange as of May 13, 2026, according to SIX Group as of 05/13/2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Bachem Holding AG
• Sector/industry: Specialty chemicals / Peptide manufacturing
• Headquarters/country: Switzerland
• Core markets: US, Europe, Asia
• Key revenue drivers: Custom peptide synthesis, GMP manufacturing
• Home exchange/listing venue: SIX Swiss Exchange (BANB)
• Trading currency: CHF

Bachem Holding AG: core business model

Bachem Holding AG develops and manufactures peptides and oligonucleotides primarily for pharmaceutical and biotechnology companies worldwide. Headquartered in Bubendorf, Switzerland, the company operates production sites in Europe and the US, enabling it to serve clients under Good Manufacturing Practice (GMP) standards. Its catalog and custom synthesis offerings support research, development, and commercial-scale production of peptide-based drugs. Bachem reported sales of CHF 434.9 million for the fiscal year 2023 (published March 2024), according to Bachem IR as of 03/2024.

The business model focuses on long-term partnerships with biotech firms, providing scalability from early-stage research to market supply. Bachem's US facility in Torrance, California, plays a crucial role in serving North American customers, reducing lead times and ensuring compliance with FDA regulations. This geographic footprint enhances its appeal to US investors tracking exposure to the booming peptide therapeutics market.

Main revenue and product drivers for Bachem Holding AG

Revenue is driven by two main segments: catalog products (standard peptides for research) and custom manufacturing (tailored GMP peptides for clinical and commercial use). In 2023, custom manufacturing accounted for about 70% of sales, fueled by demand for GLP-1 agonists and other peptide hormones used in obesity and diabetes treatments. North America contributed 47% of group sales in that period (published March 2024), per Bachem annual report 03/2024.

Key products include APIs for blockbuster drugs like semaglutide and complex peptides for oncology research. Bachem's expertise in solid-phase synthesis and large-scale production positions it well amid the US biotech sector's growth, where peptide drugs represent a growing share of pipelines according to industry analyses.

Industry trends and competitive position

The peptide therapeutics market is expanding rapidly, projected to reach $70 billion globally by 2030, driven by advances in metabolic disease treatments and precision medicine. Bachem competes with players like PolyPeptide Group and AmbioPharm but differentiates through its integrated services and US presence. For US investors, Bachem offers indirect exposure to domestic biotech innovation without the volatility of early-stage developers.

Why Bachem Holding AG matters for US investors

Bachem Holding AG provides US investors with a stable play on the US biotech ecosystem, as nearly half its revenue stems from North American clients developing next-generation therapies. Listed on the SIX Swiss Exchange, the stock offers access to peptide manufacturing growth, a niche critical to FDA-approved drugs. Its US production site ensures relevance to American regulatory standards and market dynamics.

Conclusion

Bachem Holding AG stands as a reliable supplier in the peptide sector, with strong ties to US biotech demand driving its performance. While market fluctuations in pharma R&D can impact orders, the company's diversified client base and production capabilities provide resilience. Investors monitoring biotech supply chains will find Bachem's developments noteworthy.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.